Black Diamond Therapeutics Inc (BDTX) Stock Price, Quote & News

Company Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also develo...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 252 0848

Website: www.blackdiamondtherapeutics.com

Address:

One Main Street, 14th Floor, Cambridge, United States

Icemanrush16 Dec. 26 at 5:03 PM

$BDTX bottom is set - up from here

0 · Reply

NuclearNetWorth Dec. 25 at 10:15 AM

$BDTX Investor focus is migrating toward execution sequencing, because growth without leverage now attracts skepticism. The upside case requires evidence, not projection.

0 · Reply

100K2022 Dec. 24 at 6:42 PM

$BDTX nuts deep 10K shares! Let’s go

2 · Reply

Icemanrush16 Dec. 24 at 4:28 PM

$BDTX in - looks solid

0 · Reply

signaljumper Dec. 24 at 4:05 PM

$BDTX Looks Like we find a bottom. Now good Chance to move Up in the coming weeks

0 · Reply

questionable1 Dec. 22 at 2:29 PM

$BDTX

0 · Reply

Invest2live Dec. 20 at 5:25 PM

$IPSC 71% already; congrats 🎈 🌿🎈 Follow for more research based stock alerts. Check out $BDTX and $TTD ; cheap now.

0 · Reply

jarias115 Dec. 20 at 6:57 AM

$BDTX might be back to 3 by mid January

0 · Reply

SuperGreenToday Dec. 19 at 2:09 AM

$BDTX Share Price: $2.54 Contract Selected: Jun 18, 2026 $2.5 Calls Buy Zone: $0.30 – $0.37 Target Zone: $0.48 – $0.58 Potential Upside: 52% ROI Time to Expiration: 181 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Nb713 Dec. 17 at 4:12 PM

$BDTX

0 · Reply

Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data

Dec 3, 2025, 7:01 AM EST - 23 days ago

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Dec 2, 2025, 4:01 PM EST - 23 days ago

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

Nov 20, 2025, 8:57 AM EST - 5 weeks ago

Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout

Nov 6, 2025, 4:01 PM EST - 7 weeks ago

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Nov 6, 2025, 7:30 AM EST - 7 weeks ago

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 10, 2025, 4:32 AM EDT - 2 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX ALEC CHRS

Aug 25, 2025, 11:13 AM EDT - 4 months ago

Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash

Aug 7, 2025, 7:30 AM EDT - 5 months ago

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 10, 2025, 6:38 AM EDT - 7 months ago

Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside

May 29, 2025, 8:00 AM EDT - 7 months ago

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 12, 2025, 4:05 PM EDT - 8 months ago

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 25, 2025, 12:58 AM EDT - 9 months ago

Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier

Mar 19, 2025, 7:00 AM EDT - 10 months ago

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Mar 13, 2025, 3:47 PM EDT - 10 months ago

Black Diamond Therapeutics: In Decline, But Why?

Mar 6, 2025, 4:01 PM EST - 10 months ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Dec 30, 2024, 3:07 PM EST - 1 year ago

Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts

Nov 5, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 3:24 PM EDT - 1 year ago

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Oct 7, 2024, 4:01 PM EDT - 1 year ago

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Sep 22, 2024, 10:00 AM EDT - 1 year ago

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Sep 14, 2024, 3:30 AM EDT - 1 year ago

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 27, 2024, 10:38 AM EDT - 1 year ago

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 1, 2024, 10:00 AM EDT - 1 year ago

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2024, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces Changes to Board of Directors

Apr 7, 2024, 6:00 PM EDT - 1 year ago

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Mar 24, 2024, 11:25 PM EDT - 1 year ago

Rise Of The Rest, Look Past Mega Caps, And Invest Elsewhere

AAPL AER AMZN BA DFH DHI GE

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 5, 2024, 4:30 PM EST - 1 year ago

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

Feb 28, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 12, 2024, 5:21 PM EST - 2 years ago

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 4, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

Dec 13, 2023, 7:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Nov 6, 2023, 7:45 AM EST - 2 years ago

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Oct 12, 2023, 8:31 AM EDT - 2 years ago

Black Diamond's BDTX-1535: A Brainy Bet In Cancer Therapy

Oct 4, 2023, 12:14 PM EDT - 2 years ago

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces CEO Transition

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

Aug 11, 2023, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:53 AM EDT - 2 years ago

Black Diamond Therapeutics: MasterKey Approach Validated With Lung Cancer Update

Jun 29, 2023, 8:57 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock

Jun 28, 2023, 6:51 PM EDT - 2 years ago

Black Diamond: On Right Track For Possible Accelerated Approval Pathway

Jun 28, 2023, 4:23 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock

Jun 27, 2023, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Jun 13, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer

Icemanrush16 Dec. 26 at 5:03 PM

$BDTX bottom is set - up from here

0 · Reply

NuclearNetWorth Dec. 25 at 10:15 AM

$BDTX Investor focus is migrating toward execution sequencing, because growth without leverage now attracts skepticism. The upside case requires evidence, not projection.

0 · Reply

100K2022 Dec. 24 at 6:42 PM

$BDTX nuts deep 10K shares! Let’s go

2 · Reply

Icemanrush16 Dec. 24 at 4:28 PM

$BDTX in - looks solid

0 · Reply

signaljumper Dec. 24 at 4:05 PM

$BDTX Looks Like we find a bottom. Now good Chance to move Up in the coming weeks

0 · Reply

questionable1 Dec. 22 at 2:29 PM

$BDTX

0 · Reply

Invest2live Dec. 20 at 5:25 PM

$IPSC 71% already; congrats 🎈 🌿🎈 Follow for more research based stock alerts. Check out $BDTX and $TTD ; cheap now.

0 · Reply

jarias115 Dec. 20 at 6:57 AM

$BDTX might be back to 3 by mid January

0 · Reply

SuperGreenToday Dec. 19 at 2:09 AM

0 · Reply

Nb713 Dec. 17 at 4:12 PM

$BDTX

0 · Reply

Invest2live Dec. 16 at 3:44 AM

$SPRO 66% already; congrats 🎊 🎈🎉 Checkout $BDTX and $ABSI

0 · Reply

Invest2live Dec. 14 at 3:15 PM

$XERS 193% already; congrats 🎉 🎊🎈 Follow for more research based stock alerts $BDTX and $ASRT; these are cheap now. Do your DD and get in.

0 · Reply

questionable1 Dec. 12 at 3:02 PM

$BDTX $2.85 needs to break then we should really gain some momentum back over $3.00. i love this company! always been solid

0 · Reply

BearsAreTasty Dec. 11 at 11:18 PM

$BDTX Loading the boat!

0 · Reply

Stock_Squatch_Watcher Dec. 11 at 6:25 PM

$BDTX Crazy this was sitting just below $5.00 right before the P2 data drop and we got the “sell the news” boning. I guess folks expected a halt or some miraculous data 🤷‍♂️ which was never intended. They showed very good P2 lung results and are progressing to P3 in early 2026, AND saw activity for brain cancer treatment as a secondary effect to boot. IMO, once folks realize the value of what was presented this should start climbing…a great entry point now for a moderate risky play with huge upside reward potential. ✌️🍀🦶🏿

0 · Reply

Invest2live Dec. 10 at 9:12 PM

$BDTX $BITF $SKYT $SKYT 95% already; congrats 🎈🌿🎈 $BDTX is on sale

0 · Reply

StoicStocks Dec. 10 at 7:06 PM

$BDTX What do these guys have to do to move the stock up? Cure cancer or something? Oh, wait...

0 · Reply

Invest2live Dec. 9 at 4:09 PM

$NGD 1050% already; congrats 🎉 🎊🎈 Checkout $BDTX and $TTD for long after your DD.

0 · Reply

RakeTheProfit Dec. 8 at 10:48 PM

$BDTX RSI coming into the sweet spot and oversold. Loading up some more at these levels. Always overreaction at earnings and even positive clinical readouts for the inpatient ones. Still like this one.

0 · Reply

StoicStocks Dec. 8 at 9:55 PM

$BDTX XCUR, up 178% on positive Phase II results. We drop 30% after outstanding phase II data. Make it make sense. Pure manipulation.

1 · Reply

ATLATL Dec. 8 at 3:07 PM

$BDTX Now, we sit at cash for the next seven months. Perhaps there's a milestone payment or partnership, but that seems to be the story here.

1 · Reply

Bbboston Dec. 5 at 5:08 PM

$BDTX Somebody picked up a chuck of shares early in the session. That what I think triggered that early jump.

0 · Reply

Market Cap	152.12M
Revenue (ttm)	0.00
Net Income (ttm)	-69.68M
EPS (ttm)	N/A
PE Ratio	7.08
Forward PE	5.35
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	569,800
Avg Vol	1,253,216
Day's Range	N/A - N/A
Shares Out	56.98M
Stochastic %K	53%
Beta	3.33
Analysts	Strong Sell
Price Target	$10.00